Opiant Pharmaceuticals (OPNT) Stock Price
Opiant Pharmaceuticals Price
Revenue has compounded at 63.2% per year over the past 7 years to 47.79 M USD. Earnings per share have grown at 26.9% per year over the last 13 years. Opiant Pharmaceuticals's net margin stands at 6.3%, down from 11.7% several years earlier.
Opiant Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Opiant Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Opiant Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Opiant Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Opiant Pharmaceuticals Price |
|---|
Opiant Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Opiant Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 1.00 | 9.00 | 18.00 | 11.00 | 13.00 | 40.00 | 29.00 | 47.00 | 9.00 | 38.00 | 78.00 | 193.00 | 342.00 |
| – | – | – | – | 800.00 | 100.00 | -38.89 | 18.18 | 207.69 | -27.50 | 62.07 | -80.85 | 322.22 | 105.26 | 147.44 | 77.20 |
| – | – | – | 3,800.00 | 422.22 | 211.11 | 90.91 | 92.31 | 80.00 | 79.31 | 80.85 | 80.85 | 80.85 | 80.85 | 80.85 | 80.85 |
| 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 10.00 | 12.00 | 32.00 | 23.00 | 38.00 | 7.28 | 30.72 | 63.06 | 156.04 | 276.51 |
| -12.00 | -8.00 | -11.00 | -6.00 | -7.00 | 7.00 | 1.00 | -21.00 | 10.00 | -2.00 | 5.00 | -42.00 | -31.00 | -21.00 | 19.00 | 18.00 |
| – | – | – | -600.00 | -77.78 | 38.89 | 9.09 | -161.54 | 25.00 | -6.90 | 10.64 | -466.67 | -81.58 | -26.92 | 9.84 | 5.26 |
| -12.00 | -9.00 | -11.00 | -7.00 | -7.00 | 6.00 | 1.00 | -21.00 | 11.00 | -1.00 | 3.00 | -44.00 | -20.00 | 8.00 | 3.00 | 1.00 |
| 33.33 | -25.00 | 22.22 | -36.36 | – | -185.71 | -83.33 | -2,200.00 | -152.38 | -109.09 | -400.00 | -1,566.67 | -54.55 | -140.00 | -62.50 | -66.67 |
| 1.04 | 1.43 | 1.75 | 1.81 | 1.91 | 2.24 | 4.39 | 2.99 | 5.34 | 4.25 | 5.92 | 5.92 | 5.92 | 5.92 | 5.92 | 5.92 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Opiant Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Opiant Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Opiant Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Opiant Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Opiant Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Opiant Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Opiant Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Opiant Pharmaceuticals business model & stock analysis
Opiant Pharmaceuticals SWOT Analysis
Strengths
Opiant Pharmaceuticals Inc possesses several strengths that contribute to its success in the pharmaceutical industry.
- Strong portfolio: Opiant has a robust portfolio of opioid overdose and addiction treatment options, which gives the company a competitive advantage.
- Established reputation: The company has built a strong reputation for its expertise in developing innovative pharmaceutical solutions.
- R&D capabilities: Opiant invests significantly in research and development, allowing it to stay at the forefront of medical advancements.
- Strategic partnerships: Opiant has strategic collaborations with key industry players, enhancing its market presence and expanding its customer base.
Weaknesses
Opiant Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and performance.
- Dependency on a few products: The company's revenue heavily relies on a limited number of products, making it vulnerable to market fluctuations.
- Regulatory challenges: The pharmaceutical industry is subject to stringent regulatory controls, which could result in delays or obstacles for product approvals.
- Dependency on key personnel: Opiant's success is partially dependent on key personnel, posing a risk in case of talent attrition or succession planning issues.
- Financial constraints: Limited financial resources may limit the company's ability to finance large-scale research and development projects.
Opportunities
Opiant Pharmaceuticals Inc can leverage the following opportunities to enhance its market position and achieve further growth.
- Rising demand for opioid addiction treatments: The increasing awareness about opioid addiction presents an opportunity for Opiant to expand its customer base and revenue.
- Partnerships for international expansion: Collaborations with international pharmaceutical companies can enable Opiant to enter new markets and reach a wider audience.
- Exploring new therapeutic areas: The company can invest in diversified research to cater to emerging medical needs and tap into new treatment markets.
- Government initiatives and funding: Support from government bodies and funding for research and development activities can facilitate Opiant's growth and product development.
Threats
Despite its strengths, Opiant Pharmaceuticals Inc faces certain threats that may affect its operations and profitability.
- Intense competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share and intellectual property rights.
- Market volatility: Fluctuations in market conditions, pricing pressures, and changing regulatory landscapes can impact Opiant's ability to generate sustainable revenue.
- Intellectual property risks: The company's patents and intellectual property may face challenges from competitors or legal infringements.
- Adverse drug events: Safety concerns or adverse reactions associated with Opiant's products could lead to product recalls or regulatory sanctions.
Opiant Pharmaceuticals Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Opiant Pharmaceuticals Segments
Opiant Pharmaceuticals Revenue by Segment
3 Years
5 Years
Max
Details
Opiant Pharmaceuticals Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Opiant Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Opiant Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Opiant Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Opiant Pharmaceuticals stock splits
Opiant Pharmaceuticals Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/14/2022 | -1.52USD | - | 3.74 MUSD | - | 2022 Q3 |
| 8/11/2022 | -1.39USD | - | 4.72 MUSD | - | 2022 Q2 |
| 5/10/2022 | -0.93USD | - | 5.99 MUSD | - | 2022 Q1 |
| 3/15/2022 | -0.01USD | - | 13.46 MUSD | - | 2021 Q4 |
| 11/11/2021 | 0.22USD | - | 12.31 MUSD | - | 2021 Q3 |
| 8/5/2021 | -0.29USD | - | 8.33 MUSD | - | 2021 Q2 |
| 5/11/2021 | -0.72USD | - | 5.37 MUSD | - | 2021 Q1 |
| 3/4/2021 | 0.07USD | - | 9.34 MUSD | - | 2020 Q4 |
| 11/12/2020 | -0.21USD | - | 7.87 MUSD | - | 2020 Q3 |
| 8/6/2020 | -0.25USD | - | 6.17 MUSD | - | 2020 Q2 |
Opiant Pharmaceuticals shareholder structure
| % | Name |
|---|---|
7.16339% | |
3.61480% | |
3.29184% | |
3.22246% | |
2.47318% | |
2.31045% |
Opiant Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
27.30% | SEC ↗ | |
24.00% | SEC ↗ | |
22.50% | SEC ↗ | |
11.20% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.30% | SEC ↗ | |
7.40% | SEC ↗ | |
7.40% | SEC ↗ |
Opiant Pharmaceuticals Executives and Management Board
10 members · avg. age 62 · 30 % women
Dr. Roger Crystal (45)
Chief Executive Officer, Director · since 2009
1.48 M USD
Management
Mr. Phil Skolnick (75)
Chief Scientific Officer
Mr. David O'Toole (63)
Chief Financial Officer
Board of Directors
Mr. Craig Collard (56)
Independent Director
Mr. Thomas Thomas (64)
Independent Director
Ms. Ann MacDougall (68)
Independent Director
Mr. Richard Daly (61)
Independent Director
Dr. Gabrielle Silver (48)
Independent Director
Dr. Lorianne Masuoka (60)
Independent Director
Frequently asked questions about Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing medications for treating addictions and drug overdose emergencies. Their business model revolves around the research, development, and commercialization of innovative therapeutic solutions. Opiant focuses on addressing the opioid crisis through the development of opioid antagonists, rescue medications, and other treatment options. By leveraging their expertise in addiction medicine, Opiant aims to provide effective solutions for patients, healthcare providers, and first responders. With a strong commitment to improving public health, Opiant Pharmaceuticals Inc. works diligently to develop and deliver advanced pharmaceutical products that combat addiction and save lives.
Opiant Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Opiant Pharmaceuticals Inc in the market include Emergent BioSolutions Inc, Adapt Pharma Inc, and Kaleo, Inc.
Opiant Pharmaceuticals Inc is a pharmaceutical company specializing in the development of treatments for addiction and overdose. Founded in 2005, Opiant has focused on addressing the opioid crisis through research and innovation. The company has a strong background in opioid antagonist technology, working on advanced formulations of naloxone, a life-saving medication used to reverse opioid overdoses. Opiant Pharmaceuticals Inc has partnered with government agencies, non-profit organizations, and industry leaders to develop and commercialize opioid overdose treatments. With a commitment to saving lives and improving public health, Opiant Pharmaceuticals Inc continues to play a crucial role in combating the opioid epidemic.
Opiant Pharmaceuticals Inc has achieved significant milestones throughout its history. One of the major accomplishments includes the development and FDA approval of NARCAN Nasal Spray, a life-saving medication used to reverse opioid overdose. The company has also made strides in the treatment of opioid use disorder with the development of nalmefene, a potential opioid antagonist therapy. Opiant Pharmaceuticals Inc continues to innovate and invest in research and development to address the growing opioid epidemic and improve patient outcomes. Through their dedication and focus, Opiant Pharmaceuticals Inc remains at the forefront of creating effective solutions for opioid-related medical emergencies.
Opiant Pharmaceuticals Inc is primarily present in the United States.
Opiant Pharmaceuticals Inc represents a strong commitment to advancing public health through innovative pharmaceutical solutions. The company focuses on developing treatments for life-threatening addictions and drug overdoses. With a dedication to research and development, Opiant strives to improve patient outcomes and address critical medical needs. Through partnerships and collaborations with healthcare professionals, Opiant aims to provide effective and safe interventions for addiction-related disorders. By leveraging its expertise in the field, Opiant Pharmaceuticals Inc remains dedicated to making a positive impact on the lives of individuals struggling with substance abuse.
7 analysts currently rate the Opiant Pharmaceuticals stock: 0 recommend buying, 4 holding and 3 selling.
The Opiant Pharmaceuticals share (OPNT) is listed on 1 stock exchanges, including: NASDAQ (OPNT).
Opiant Pharmaceuticals Inc. is a leading biotechnology company in the USA specializing in the development and commercialization of drugs for drug abuse and addiction. The company aims to find innovative solutions to challenges arising from drug abuse and addiction through its various divisions. The first division of Opiant Pharmaceuticals focuses on opioid addiction therapy. The company has concentrated on the development of naloxone nasal spray, which is used to treat opioid overdoses. This product is easy to use and has already saved many lives. The second division focuses on the treatment of alcohol addiction. The company has developed a medication called OPNT003, also known as Nalmefene, which reduces cravings and desire for alcohol and helps patients overcome their addiction. It is the only medication of its kind approved in the USA. The third division of Opiant Pharmaceuticals is dedicated to the treatment of bulimia and binge-eating disorders. Here, the company has developed a medication called OPNT002, which reduces appetite and slows down carbohydrate metabolism. The medication has proven effective and will soon be submitted for approval. The fourth and final division of Opiant Pharmaceuticals is the development of medications for the treatment of narcolepsy and other sleep-wake cycle disorders. The company has developed various medications aimed at reducing the symptoms of these disorders and normalizing the sleep-wake cycle. Based on these examples, it is evident that Opiant Pharmaceuticals focuses on the development of medications aimed at treating physical dependencies and disorders. The company's goals are comprehensively covered through its various divisions. Opiant Pharmaceuticals' business model is based on the development and commercialization of innovative solutions for the treatment of addictions and disorders. The company works closely with regulatory authorities and medical institutions to test the products and obtain approval. Once the products are approved, they are marketed and sold by Opiant Pharmaceuticals. To successfully implement the business model, Opiant Pharmaceuticals has built a team of experts who work closely with the various divisions of the company. The company's management has a high level of experience in the pharmaceutical industry and has an extensive network of contacts and partners. In summary, Opiant Pharmaceuticals has an innovative business model aimed at helping people overcome their addictions and disorders. Through the development and commercialization of effective medications, the company continues to be at the forefront of the pharmaceutical industry.
The revenue cannot currently be calculated for Opiant Pharmaceuticals.
The profit cannot currently be calculated for Opiant Pharmaceuticals.
The P/E ratio cannot be calculated for Opiant Pharmaceuticals at the moment.
The P/S cannot be calculated for Opiant Pharmaceuticals currently.
The Eulerpool Quality Score for Opiant Pharmaceuticals is 5/10.
The ISIN of Opiant Pharmaceuticals is US6837501039. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Opiant Pharmaceuticals is A2AFQ6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Opiant Pharmaceuticals is OPNT. The ticker symbol is used to trade Opiant Pharmaceuticals shares on the stock exchange.
Opiant Pharmaceuticals is assigned to the 'Health' sector.
The dividends of Opiant Pharmaceuticals are distributed in USD.
Opiant Pharmaceuticals stock
Opiant Pharmaceuticals Peer Group
Opiant Pharmaceuticals Ticker
Opiant Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Opiant Pharmaceuticals
Our stock analysis for Opiant Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opiant Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.